Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data.
What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show!
BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor.
I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites.
You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out.
Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"...
BTW, your own malignancy event table shows a malignancy rate BELOW background rates....???
You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you?
So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!"
BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk...
You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity...
Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
$LQDA Company unexpectedly negotiates all legal affairs and explicitly states it will not raise, despite a huge sum of money expected to be remitted. Yeah, all signals for a BO.
Oz retweeted
Replying to @mahesh_shenai
@mahesh_shenai, Although we have never met, I addressed Dr. Mallika Mundkur at the @FDA's CNPV public meeting, whom I understand is your wife.
After reading nearly 20 of your posts concerning Huntington’s disease (HD) and AMT-130, I have to ask: Are you evaluating the totality of the evidence, or predominantly searching for reasons to discount it?
You repeatedly express hope that you will someday treat Huntington’s disease patients. But how much direct experience have you had with our community? Have you spent meaningful time with symptomatic patients across disease stages, witnessed their progressive neurological decline, or spoken with families about their risk tolerance?
I ask because I have.
HD has devastated three generations of my family. My grandmother died after years of suffering. Her chorea was so severe that she wore padded mittens for nearly four years to prevent her involuntary movements from dislodging her feeding tube.
I was nearly my daughter’s age when my grandmother developed symptoms. Now both my daughter and son are watching their grandfather and aunt experience the same disease. My father is in the middle stages of Huntington’s disease, while my aunt is further along in its devastating progression. As a mother, I live with the painful reality that my children may one day witness this same deterioration in me—or, even more heartbreaking, experience it themselves.
What I witnessed as a little girl, my children are witnessing today. Different generations, the same devastating cycle we are desperately trying to break.
The psychological consequences are equally profound. A fellow Michigander and HD advocate recently lost her father to suicide. Another Michigan chapter board member nearly lost her niece, and several HD friends have lost loved ones to suicide. Suicide risk among people with Huntington’s disease is substantially higher than in the general population.
Why? Imagine caring for someone you love while witnessing years of relentless neurological deterioration, all while knowing you could face the same fate. And even if you escape inheriting the mutation, you may carry the lifelong burden of survivor’s guilt as those you love continue to suffer. This is the profound, multigenerational trauma of Huntington’s disease.
More than 40,000 Americans live with HD, and over 200,000 are at risk. Those figures do not include the countless caregivers and relatives whose lives are also affected.
Your anecdote about a surgeon with another movement disorder reinventing his professional life was particularly revealing. When I read it, I immediately questioned your firsthand understanding of HD.
HD does not afford patients the luxury of simply reinventing their lives. It progressively damages the brain circuits responsible for cognition, judgment, behavior, movement, and independence. Symptoms can worsen over 10–25 years, gradually taking away the ability to work, communicate, maintain relationships, swallow, walk, talk, and care for oneself.
The ability to reinvent one's life requires precisely the neurological capacities HD progressively destroys. HD takes away the ability to meaningfully participate in life altogether.
The 2024 HD Symptoms and Treatment Impact Survey found that nearly three-quarters of respondents would accept treatment risks for five years without progression, while approximately 35% would accept risks for even three years.
Three more years raising children. Five more years working, communicating, remembering, and living independently. More birthdays, graduations, and time with family.
Then consider the economic consequences of inaction. Over 10–25 years, HD families will face neurologists, psychiatrists, hospitalizations, expensive chorea and psychiatric medications, physical and occupational therapy, speech and swallowing therapy, mobility equipment, home modifications, specialized residential care, and eventually around-the-clock assistance.
HD removes two people from the workforce: the patient and the family member who becomes their caregiver. Families lose wages, insurance benefits, retirement savings, and years of financial security. Many conventional care facilities lack the specialized neurological and behavioral resources required for HD, leaving families with limited options.
These costs accumulate across households, employers, Medicare, Medicaid, disability programs, and society.
When evaluating the risks and costs of treatment, why is the cost of inaction so often treated as though it were zero?
If AMT-130 meaningfully preserves independence, the potential economic and societal benefits deserve consideration.
You have described yourself as one of approximately 80 U.S. neurosurgeons with expertise relevant to this procedure. If AMT-130 does not meet your personal threshold for clinical adoption, that is your judgment. But your threshold is not the FDA's regulatory standard, nor should it determine the choices available to every informed patient and qualified physician.
Other neurosurgeons may recognize the broader significance of this investigational gene therapy. If its clinical benefits are confirmed, AMT-130 could help transform how we approach inherited neurodegenerative disorders beyond HD.
Regarding surgical risk, stereotactic neurosurgery has been performed in humans since 1947. Trial experience suggests the procedure has generally been tolerated.
But the question is not whether neurosurgery carries risk. It does. The question is whether those risks are acceptable relative to the potential benefit for patients facing a progressive, fatal disease without an approved disease-modifying treatment.
Your professional risks and our personal risks may look entirely different.
For you, this is a discussion of procedural complications, evidence, and professional responsibility. For us, it is progressive neurological deterioration, dependency, and premature death.
The reported AMT-130 findings, including favorable Total Functional Capacity trajectories compared with external controls, deserve serious consideration. TFC measures employment, financial management, domestic responsibilities, daily living, and care requirements. It measures the independence HD progressively takes away.
Scientific skepticism is essential, but it must be applied symmetrically.
Our community has also been wounded by regulatory rhetoric. @VPrasadMDMPH, your wife’s former boss, recently compared patients pursuing unproven treatments to a drowning person reaching for a blade. Regardless of the intended scientific warning, such language risks reducing informed, deeply personal benefit-risk decisions to acts of desperation, overlooking the devastating consequences patients and families face without treatment.
Our willingness to accept uncertainty is not desperation. It reflects a rational understanding of what HD will otherwise take from us.
Imagine watching someone you love progressively lose the ability to think, communicate, walk, swallow, or even recognize the people they love most. Now imagine living with the knowledge that the same devastating disease could one day affect you, your children, your siblings, or generations of your extended family. This is the reality of Huntington’s disease.
What would a few additional years together mean? What would you do to break the cycle?
I am not asking you to abandon scientific standards. I am asking you to recognize that the consequences of waiting are as real as the risks of treatment.
The absence of treatment is not the absence of risk. It is continued disease progression, escalating dependency, enormous psychological and economic suffering, and irreversible neurological loss.
You may see an investigational neurosurgical procedure that has not met your preferred evidentiary threshold. We see a potential opportunity to preserve the ability to think, communicate, work, love, and remain present in our families' lives.
We are asking for scientific judgment that accounts for the full reality of Huntington’s disease.
P.S. Go Blue! 〽️💙💛
#HuntingtonsDisease
#RareDisease
$LQDA Think about why Liquidia chose to settle all legal accounts with $UTHR..when it would make sense for them to appeal in the federal circuit and likely win. Patent infringement gets overturned all the time. So why settle after years and years of litigation? BUYOUT TALKS
Oz retweeted
My thoughts on why I believe QURE has cleared the bar. Free post below.
botn.bio/p/the-three-year-qu…
I’m guessing if the market doesn’t like something about the data, it’s that patients getting 36 weeks of treatment instead of those getting the full 52 weeks of treatment did not maintain their responses when taken off the drug nearly as well.
Probably explains the negative reaction (?) but to me it seems like a nitpick because….
The phase 3 trial is a full 52 week induction treatment period. The regimen they’re *actually* going to be using is showing unprecedented durability of effect, even off treatment. Even then, in the real world we are probably still talking about a 3 month dosing interval anyway, not quitting the drug completely (which is also what NKTR would want, obviously - chronic treatment). The sparse dosing and durability are just good for the flexibility of not risking losing your hair with dosing interruptions (daily/twice daily dosing with other competitors).
So that’s my shot at an explanation. Frankly it would be funny to see the stock sell off on not producing unprecedented *enough* results with an asset/indication that people have been saying is NPV neutral to negative. But, hey 🤷🏻♂️
tl;dr - market seems to care that the durability is not as good in patients who didn’t get treated as long (36 weeks), but it’s not clear to me why we care about that since the P3 trial will be a full year anyway.
$NKTR AA off-treatment durability data. 75% maintained their SALT<20 response at 4 months of no treatment, and 63% after 6 months.
They even saw some continued deepening of effect *without* new treatment - they gained another SALT<10 responder.
This off-treatment durability is a unique and highly desirable feature in alopecia areata. As discussed elsewhere:
1). The current SoC (JAKi) loses efficacy rapidly when stopped/interrupted. In the real world, dose interruptions happen often for any number of reasons.
2). Interruptions of treatment when using drugs that lose efficacy rapidly when stopped is a big problem for this disease specifically. Growing hair takes time. Literally years for people with longer hair styles. AA makes hair fall out at the follicle. If you have even a short term lapse in treatment, it has long term consequences in this disease - unlike most I&I conditions where you simply resume the drug and get your response back, that process can take *years* in AA.
So now, $NKTR can not only say they have the first to market safe biologic for AA, beating out JAKi with their 5 point black box warning (for this relatively cosmetic condition). Now they can also say “we have major off treatment durability, so in the real world when patients miss a dose, their hair isn’t just going to fall out”.
This indication seems to have been written to $0 net present value for $NKTR recently. I really do not understand why. There’s a product here.
$SLS Every time I see an SLS bull posting some nonsense, I am reminded of the fact that most humans are retarded.
1
4
357
Oz retweeted
Replying to @ausiman14 @adamfeuerstein
Also 78-79 of these implied healthy patients died so let's not pretend you know what you are talking about.
If $ABVX gets bought out by BP, I’m calling it here:
Either A) $170-180/sh + $40 CVR.
B) $190-200/sh
Knowing Marc’s history and patience, he will seek the max value, even if it takes months.
The uncertainty for Crohn’s will unfortunately requires a call option.
3
851







